Dossier assessment

Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-04
Last updated

Report documents

  1. Extract of dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 433 kB, EN, not accessible
  2. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 561 kB, DE, not accessible

Dossier assessment

Indication:

Adult patients with previously untreated chronic lymphocytic leukaemia

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2023-07-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-04
Commission
Commission awarded on 26.01.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-88
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-77
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-78
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-60
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-39
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Ibrutinib - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-04
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G14-11
    Last updated

    Status: Commission completed

  8. Addendum

    Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04

    Project no.
    A23-54
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form